OLMA
Olema Pharmaceuticals, Inc.
Next earnings Aug 10, 2026 · consensus $-0.56 EPS
Last earnings -6.0% on 2026-05-12
$11.39
▼ -0.35%$11.39▲ +175.79%
over 1Y
L $4.13EODHDH $35.83
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.3%
1W+13.9%
1M-11.8%
3M-16.7%
YTD-54.9%
1Y+175.8%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 19 analysts
Buy
Pre-revenue biotech burning $147M/yr with only $48M cash — binary OPERA-01 readout in fall 2026 on a depleted balance sheet.
Olema is a clinical-stage biopharma with zero product revenue and a widening loss profile: net loss expanded to -$162M in FY2025 from -$129M in FY2024 (-25.5% YoY), driven by R&D ramp to $158M (+26.6%) as OPERA-01 and OPERA-02 advance. Management explicitly states they 'expect to incur significant and increasing losses for the foreseeable future,' and the entire equity story rests on palazestrant — a CERAN/SERD for ER+/HER2- metastatic breast cancer — with top-line Phase 3 OPERA-01 data due fall 2026 and a potential NDA in 2027. This is a binary, single-asset bet.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$71.5M | -$107M | -$105M | -$142M | -$179M |
| Net income | -$71.1M | -$105M | -$96.7M | -$129M | -$162M |
| Diluted EPS | -$1.80 | -$2.62 | -$2.14 | -$2.20 | -$1.87 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$944M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-16.4%
FCF yield-14.8%
Quality & risk
ROIC (est.)-29.5%
Free cash flow-$147M
Total debt—
Net cash$48.3M
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+27.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has skewed negative — read the flagged items.
- 8-K Shareholder vote2026-06-23
Annual meeting vote results; routine director/auditor ratification disclosure.
- 8-K Reg FD disclosure2026-05-26
Reg FD investor/conference materials posted; no new financial commitments.
- 8-K Reg FD disclosure2026-05-21
Reg FD update — likely conference presentation on palazestrant program.
- 8-K Earnings results2026-05-12
Q1'26: continued operating losses, R&D-heavy spend pressures $48M cash base.
- 10-Q Quarterly report2026-05-12
Q1'26: continued operating losses, R&D-heavy spend pressures $48M cash base.
- 8-K Material agreement2026-05-01
Entered new material agreement creating direct financial obligation (debt/financing).
- 8-K Officer / director change2026-04-29
2026 proxy: routine board, comp and auditor ratification items.
- DEF 14A Proxy statement2026-04-29
2026 proxy: routine board, comp and auditor ratification items.
- 10-K Annual report2026-03-16
FY25 net loss $162M; cash fell 65% to $48M — funding need before OPERA-01 readout.
Recent filings
all on EDGAR ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗8-KPeriod ending 2026-06-172026-06-23open ↗
Frequently asked
- Is Olema Pharmaceuticals, Inc. (OLMA) a buy?
- OLMA currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Pre-revenue biotech burning $147M/yr with only $48M cash — binary OPERA-01 readout in fall 2026 on a depleted balance sheet.
- What is Olema Pharmaceuticals, Inc.'s quality score?
- OLMA scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001750284, latest 10-Q filed 2026-05-12) · EODHD · analysis by claude-code · as of 6/25/2026, 2:38:22 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.